Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Summary

This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.

Timeline

Start

2021-06-10

Primary completion

2022-06-08

Completion

2022-06-29

Publications

• Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, Serrao R, Guttman-Yassky E, Sticherling M, Csernus AE, Moreno-Arrones OM, Hamilton C, Cassella J. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026 Apr;94(4):1134-1143. doi: 10.1016/j.jaad.2025.11.070. Epub 2025 Nov 27.

Drugs

Indications